Compare SBH & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBH | ALVO |
|---|---|---|
| Founded | 1964 | 2013 |
| Country | United States | Luxembourg |
| Employees | 27000 | 1460 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2006 | N/A |
| Metric | SBH | ALVO |
|---|---|---|
| Price | $13.85 | $4.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $17.25 | $8.00 |
| AVG Volume (30 Days) | ★ 1.3M | 721.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.17 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $3,701,424,000.00 | N/A |
| Revenue This Year | $2.20 | $13.28 |
| Revenue Next Year | $1.82 | $18.63 |
| P/E Ratio | ★ $15.41 | $18.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.48 | $2.94 |
| 52 Week High | $17.92 | $9.94 |
| Indicator | SBH | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 64.02 |
| Support Level | $13.46 | $3.09 |
| Resistance Level | $15.75 | $5.46 |
| Average True Range (ATR) | 0.44 | 0.28 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 94.34 | 76.06 |
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. The company operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, Netherlands, and other geographical regions. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. The products offered by the company include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.